Welcome to our dedicated page for Aimei Health Technology Co. SEC filings (Ticker: afjku), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Struggling to spot the next health-tech deal hidden in Aimei Health Technology Co., Ltd’s dense SPAC disclosures? Each 200-page prospectus, 10-K, or 8-K is packed with trust-account math, sponsor warrants, and redemption clauses that can affect your return long before a merger closes.
Stock Titan’s AI turns those complexities into clarity. Our platform delivers real-time alerts the moment an Aimei Health Technology Co., Ltd 8-K material events explained filing appears on EDGAR and produces plain-English summaries so you can see, in seconds, whether a definitive agreement or extension vote is on the table. Need ownership details? The dashboard highlights Aimei Health Technology Co., Ltd Form 4 insider transactions real-time, letting you monitor sponsor purchases, redemptions, or warrant exercises without scrolling through multiple exhibits.
Key filings we cover and decode:
- 10-K annual report – cash held in trust, deadline milestones, and sponsor economics, all in an Aimei Health Technology Co., Ltd annual report 10-K simplified format.
- 10-Q quarterly update – trust interest income and expense trends inside the Aimei Health Technology Co., Ltd quarterly earnings report 10-Q filing.
- 8-K – every material event, from LOIs to business-combination announcements, with Aimei Health Technology Co., Ltd 8-K material events explained.
- DEF 14A proxy statement – see Aimei Health Technology Co., Ltd proxy statement executive compensation details and vote deadlines.
- Form 4 – track Aimei Health Technology Co., Ltd insider trading Form 4 transactions and other Aimei Health Technology Co., Ltd executive stock transactions Form 4.
Whether you’re comparing warrant terms, timing a redemption, or just understanding Aimei Health Technology Co., Ltd SEC documents with AI, our concise notes, key-figure extracts, and trend charts provide the Aimei Health Technology Co., Ltd SEC filings explained simply experience investors rely on. Save hours, avoid surprises, and focus on what moves SPAC valuations.
Aimei Health Technology Co., Ltd. completed a $69.0 million initial public offering of 6,900,000 Units and a $3.32 million private placement, placing $73,784,549 in a U.S. trust account invested in short-term Treasuries or qualifying money market funds until a business combination closes or funds are distributed to redeeming public shareholders. As of December 31, 2024, the company held $28,208 of cash outside the trust, reported a working capital deficit of $747,377 and a shareholders' deficit presentation reflecting 6,900,000 shares subject to redemption at $10.10 per share. The registrant recorded $31.27 million of redemptions of 2,904,267 shares and made multiple $150,000–$227,700 monthly extension deposits into the trust to extend the combination period. The filing discloses the company has not adopted a formal cybersecurity risk management program and notes reliance on third-party technologies and limited resources to investigate or remediate cyber vulnerabilities.
Aimei Health Technology Co., Ltd is a blank check company formed to complete an initial business combination and has not commenced operations. The company holds the majority of its proceeds in a trust for public shareholders, reporting $2,138 in cash, $44,511,399 in its Trust Account and total assets of $44,556,037. Ordinary shares subject to possible redemption totaled 3,995,733 at a redemption value of $11.14, and total shareholders' deficit was $(2,859,328).
For the six months ended June 30, 2025 the company reported net income of $609,632, driven by interest on trust assets of $1,064,650 offset by formation and operating costs of $455,018. The company amended and extended its combination period multiple times (now extended to September 6, 2025), issued extension promissory notes totaling $1,205,400 as of June 30, 2025, and redeemed 2,904,267 shares for approximately $31.27 million. Management disclosed substantial doubt about the company’s ability to continue as a going concern if it fails to complete a business combination within the prescribed period.
Mizuho Financial Group reports beneficial ownership of 550,600 common shares of Aimei Health Technology, representing 9.0% of the outstanding class. The filing states Mizuho has sole voting and dispositive power over these shares and that the securities are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
The filing is made by the parent holding company and discloses that related entities (Mizuho Bank, Mizuho Americas LLC) may be deemed indirect beneficial owners through a wholly owned broker-dealer subsidiary.
W. R. Berkley Corporation and its subsidiary Berkley Insurance Company report beneficial ownership of 425,361 ordinary shares of Aimei Health Technology Co., Ltd (ordinary shares, $0.0001 par). That stake represents 6.9% of the company’s outstanding shares based on the issuer’s publicly reported total of 6,121,733 shares. The filing shows shared voting and shared dispositive power over the 425,361 shares rather than sole control.
The statement notes the securities are held in the ordinary course of business and were not acquired to change or influence control of the issuer. Reporting persons are organized in Delaware and list a Greenwich, CT address for their principal business office.
FAQ
What is the current stock price of Aimei Health Technology Co. (afjku)?
